Skip to main content

Table 1 End-points of randomized trials

From: Management of persistent anal canal carcinoma after combined-modality therapy: a clinical review

Trial

Patients

Study design

Primary end-point

Secondary end-point

ACT I [2]

560

CRT vs RT

LC; RFS; CFS; OS

-

Intergroup [3]

310

CRT vs RT

LC; CFS; OS; DFS

-

EORTC [4]

110

CRT vs RT

LC

OS; CFS

UKCCCR [18]

856

CRT vs RT

LC

OS; morbidity

  1. LC local control; RFS: relapse free survival, CFS colostomy free survival, OS overall survival, DFS disease free survival.
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us